Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Global diabetes drug Ozempic (semaglutide) has now been launched in India by Danish pharmaceutical major Novo Nordisk. In an ...

Novo Nordisk has approached the Delhi High Court to prevent Dr Reddy’s Laboratories from manufacturing and exporting ...

Looking to expand its footprint in the booming glucagon-like peptide (GLP-1) market, Danish drugmaker Novo Nordisk has ...

Novo Nordisk has launched Ozempic in India at ₹2,200 per week, expanding diabetes treatment options even as patent disputes ...

Ozempic, which is injected once a week under careful medical supervision, is said to help control diabetes and help Type 2 ...

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

We recently published 13 Best ADR Stocks to Invest In. Novo Nordisk A/S (NYSE:NVO) is one of the best ADR stocks. Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus ...

In early December 2025, Novo Nordisk reported phase 3 Evoke and Evoke+ trial results showing oral semaglutide did not improve ...